| Customization: | Available |
|---|---|
| CAS No.: | 654671-77- |
| Formula: | C16h18f6n5o5 |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Product name: Sitaglipti phosphate monohydrate
CAS No: 654671-77-
Sitaglipti phosphate monohydrate is a selective and potent inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4). It is primarily used in the management of type 2 diabetes mellitus. By inhibiting DPP-4, sitaglipti increases the levels of incretin hormones, which help regulate blood glucose levels. This results in enhanced insuli secretion and reduced glucagon release, contributing to improved glucose control. Sitaglipti phosphate monohydrate is the monohydrate form of sitaglipti phosphate, providing stability and ease of formulation in pharmaceutical preparations.
Application and Effect
Sitaglipti phosphate monohydrate is primarily used in the treatment of type 2 diabetes. It works by inhibiting the enzyme DPP-4, which is responsible for breaking down incretin hormones like GLP-1 (glucagon-like peptide-1) and GIP (gastric inhibitory polypeptide). These hormones play a crucial role in regulating blood sugar levels by stimulating insuli secretion and inhibiting glucagon release from the pancreas. By increasing the availability of these hormones, sitaglipti helps lower postprandial (after meal) blood glucose levels, thus providing better glycemic control. The drug is often used as an adjunct to diet and exercise to improve blood glucose levels in adults with type 2 diabetes. Sitaglipti phosphate monohydrate is commonly prescribed either as monotherapy or in combination with other antidiabetic agents, such as metformin, sulfonylureas, or insuli. It is well-tolerated, with a low risk of causing hypoglycemia (low blood sugar) compared to other antidiabetic medications. In addition to its glucose-lowering effects, sitaglipti may have potential benefits for cardiovascular health, with ongoing studies investigating its effects on heart disease in diabetic patients. It may also contribute to improved beta-cell function, which is essential for insuli production. Overall, sitaglipti phosphate monohydrate offers a safe and effective treatment option for managing type 2 diabetes.
Specifications:
| Composition | C16H18F6N5O5 |
| Assay | 99% |
| Appearance | White to off-white solid |
| CAS No. | 654671-77- |
| Packing | Small and bulk |
| Shelf Life | 2 years |
| Storage | Store in cool and dry area |
| Certification | ISO. |
){kind=link}